ArticleEpilepsia open2025
Antiseizure medication choice in diffuse glioma: A single-center population-based experience.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antiseizure medication choice in diffuse glioma: A single-center population-based experience.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveSeveral antiseizure medications (ASMs) can be considered as first-line treatment for glioma-associated epilepsy (GAE). We aimed to find out, if there are subgroups of glioma patients which may benefit from different first-line ASMs.
methodsAll diffuse glioma (grade 2-4) patients, who were in contact with Helsinki University Hospital Neurology or Oncology Departments during 2013-2015, were recognized from medical records. Follow-up data was retrospectively collected of all GAE patients living in Helsinki for 5 years from diagnosis of glioma, or until death.
resultsA total of 121 patients with GAE fulfilling inclusion criteria were identified. Forty-nine (40.5%) had grade 2 glioma, 18 (14.9%) had grade 3 glioma, and 54 (44.6%) had grade 4 glioma. The most common first ASM was oxcarbazepine (39.2%), followed by levetiracetam (22.5%), carbamazepine (19.3%), phenytoin (10.8%) and valproic acid (8.3%). The first ASM was retained in use in 70 (57.9%) patients until the end of follow-up. Among patients with low-grade glioma, oxcarbazepine was favored, whereas grade 4 glioma patients more often received levetiracetam as first ASM. At the end of follow-up, the retention rate of levetiracetam as first ASM was higher than retention rate of other ASMs in grade 4 glioma patients (p 0.002). Patients who initiated valproic acid as first ASM underwent more ASM changes than patients who initiated other first-line ASM (p 0.005). SIGNIFICANCE: Levetiracetam seems to be a favorable first-line treatment for GAE, especially for patients with grade 4 glioma. For grade 2-3 glioma patients, oxcarbazepine may be a reasonable option. PLAIN LANGUAGE SUMMARY: Grade 2-4 gliomas are central nervous system tumors originating from glial cells, and epilepsy is common in glioma patients. We found that levetiracetam was favored as first antiseizure medication for patients with malignant, grade 4, glioma. For patients with slower-growing tumors, grade 2-3 gliomas, oxcarbazepine may be a reasonable choice for first antiseizure medication. The findings highlight the need for individual assessment in the use of antiseizure medications in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.